Inclusion Criteria:

          1. Capable and willing to give signed informed consent which includes compliance with the
             requirements and restrictions listed in the informed consent form (ICF).

          2. Participant must be at least 18 years of age, at the time of signing the ICF.

          3. Participants must have histological or cytological confirmation of advanced malignancy
             considered to be suitable for study treatment.

          4. Eastern cooperative oncology group performance status 0-1.

          5. Life expectancy greater than 12 weeks.

          6. Progressive cancer at the time of study entry.

          7. Pharmacodynamics expansion cohorts: Participants must have at least 1 tumour suitable
             for biopsy and consent to having biopsies collected.

          8. Negative pregnancy test (urine or serum) prior to start of dosing for women of
             childbearing potential.

          9. Female participants must be post-menopausal, surgically sterile, or using an
             acceptable method of contraception for the duration of the study (from the time they
             sign consent) and for 12 weeks after the last dose of study treatment to prevent
             pregnancy.

         10. For the duration of the study (from the time they sign consent) and for 12 weeks after
             the last dose of study treatment, sexually active male participants must be willing to
             use contraception.

        Post-menopausal is defined as:

          -  No menses for 12 months without an alternative medical cause. A high follicle
             stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a
             post-menopausal state in women not using hormonal contraception or hormonal
             replacement therapy). However in the absence of 12 months of amenorrhea, a FSH
             measurement is insufficient.

          -  Radiation-induced oophorectomy with last menses greater than 12 months ago.

          -  Chemotherapy-induced menopause with greater than 12 month interval since last menses.

          -  Surgical sterilisation.

        Exclusion Criteria:

          1. Any unresolved toxicities from prior therapy common terminology criteria for adverse
             event (CTCAE) Grade ≥2 (with the exception of alopecia).

          2. Spinal cord compression or brain metastases unless definitively treated, asymptomatic,
             stable and not requiring steroids for at least 4 weeks.

          3. As judged by the Investigator, any evidence of severe or uncontrolled medical
             conditions including but not limited to:

             • Uncontrolled diabetes mellitus, uncontrolled seizures, active infection requiring
             systemic antibiotics, antifungal or antiviral drugs, severe chronic obstructive
             pulmonary disease, severe Parkinson's disease, active inflammatory bowel disease,
             psychiatric condition, active bleeding diatheses, renal transplant, or active
             infection including any participant with active hepatitis B, hepatitis C or human
             immunodeficiency virus.

          4. Any other malignancy which has been active or treated within the past 3 years, with
             the exception of in situ cancer of the cervix, non-melanoma skin cancer, ductal
             carcinoma in situ, Stage 1 Grade 1 endometrial carcinoma, or other solid tumours
             including lymphomas curatively treated with no evidence of disease for ≥5 years.

          5. Refractory nausea and vomiting or unable to swallow and retain oral medication,
             chronic gastrointestinal diseases or previous bowel resection with clinically
             significant sequelae that would preclude adequate absorption of AZD7648,
             gastrointestinal symptoms CTCAE Grade >1, history of gastrointestinal ulceration and
             gastrointestinal haemorrhage within 6 months of first study drug administration.

        6 Receiving or having received anti-cancer treatment within the following periods prior to
        the first dose of investigational product:

        (a) Cytotoxic treatment: 3 weeks, (b) Non-cytotoxic drugs: including small molecule
        investigational products: 3 weeks or 5 half-lives (whichever is longest), (c) Biological
        products including investigational immuno-oncology agents: 4 weeks, (d) Radiation with a
        limited field for palliation: 1 week (3 months for radiation to the abdomen or pelvis), (e)
        Radiation to >30% of the bone marrow or with a wide field: 4 weeks, (f) Lung radiation: 60
        days, (g) Major surgery: 4 weeks; minor surgery or biopsy: 1 week 7. During the 4 weeks
        prior to the first dose, receiving corticosteroids at a dose of >10 mg prednisone/day or
        equivalent for any reason. Ongoing low dose steroids for longer than 3 months (excluding
        inhalational, nasal, creams, lotions, and gels) are not allowed.

        8. Receiving or having received concomitant medications, herbal supplements and/or foods
        known to significantly modulate CYP3A4 activity.

        9. Prior exposure to a deoxyribonucleic acid-pharmacokinetics inhibitor or hypersensitivity
        to any excipient of the product.

        10. Cardiac dysfunction as defined by any of the following within 6 months of study entry:

        (a) Acute myocardial infarction, (b) New York Heart Association Class II/III/IV heart
        failure, (c) Unstable angina, (d) Unstable cardiac arrhythmias 11. Any of the following
        cardiac criteria:

        (a) Known reduced left ventricular ejection fraction below the institutional lower limit of
        normal, (b) Mean resting corrected QT interval (QTc) >470 milliseconds obtained from 3
        electrocardiograms in 24 hours using the Fridericia formula, (c) Any factors that increase
        the risk of QTc prolongation or arrhythmic events such as hypokalaemia, congenital long QT
        syndrome, immediate family history of long QT syndrome or unexplained sudden death under 40
        years of age 12. Inadequate hematological or organ function 13. Involvement in the planning
        and/or conduct of the study. 14. Judgement by the Investigator that the participant should
        not participate in the study if the participant is unlikely to comply with study
        procedures, restrictions and requirements.

        15. Previous enrolment in the present study. 16. For female participant only: currently
        pregnant or breast-feeding. 17. For food effect cohort only: insulin dependent diabetes.
        18. History and/or presence of coronavirus disease 2019.